Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 265

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study

Open access
Mauz-Körholz, Christine, Hasenclever, Dirk, Dörffel, Wolfgang, Ruschke, Kathrin, Pelz, Tanja, Voigt, Antje, Stiefel, Martina, Winkler, Melanie, Vilser, Constanze, Dieckmann, Karin, Karlén, Jonas, Bergsträsser, Eva, Fosså, Alexander, Mann, Georg, Hummel, Michael, Klapper, Wolfram, Stein, Harald, Vordermark, Dirk, Kluge, Regine, Körholz, Dieter · 2010 · Journal of Clinical Oncology

Abstract

Purpose: Vincristine, etoposide, prednisone, and doxorubicin (OEPA)–cyclophosphamide, vincristine, prednisone, and dacarbazine (COPDAC) is derived from standard vincristine, procarbazine, prednisone, and doxorubicin (OPPA)–cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) chemotherapy by replacing procarbazine with etoposide and dacarbazine for a potentially less gonadotoxic regimen for boys with Hodgkin's lymphoma (HL). Patients and Methods: Five hundred seventy-three pediatric patients with classical HL were enrolled onto the German Society of Pediatric Oncology and Hematology–Hodgkin's Disease (GPOH-HD) -2002 study between November 2002 and December 2005. Boys received two courses of OEPA and girls received two courses of OPPA for induction. Treatment group (TG) -2 (intermediate stages) and TG-3 (advanced stages) patients received further two or four cycles COPP (girls) or COPDAC (boys), respectively. After chemotherapy all patients received involved-field irradiation with 19.8 Gy, except for patients with early-stage disease (TG-1) in complete remission. Results: Five hundred seventy-three patients (287 males and 286 females) were less than 18 years old and fulfilled all inclusion criteria; 195 patients (34.0%) were allocated to TG-1, 139 (24.3%) were allocated to TG-2, and 239 (41.7%) were allocated to TG-3. Toxicity of OEPA-COPDAC was tolerable overall. Hematotoxicity was more pronounced with OEPA than OPPA, whereas it was less pronounced with COPDAC compared with COPP. The median observation time was 58.6 months. Overall survival and event-free survival (EFS) rates (± SE) at 5 years were 97.4% ± 0.7% and 89.0% ± 1.4%, respectively. In TG-1, overall EFS was 92.0% ± 2.0%. EFS of patients without irradiation (93.2% ± 3.3%) was similar to that of irradiated patients (91.7% ± 2.5%), confirming results of the previous GPOH-HD-95 study. In TG-2+3, EFS did not significantly differ between boys and girls (90.2% ± 2.3 v 84.7% ± 2.7, respectively; P = .12). Conclusion: In TG-2+3, results in boys and girls are superimposable. OPPA-COPP and OEPA-COPDAC seem to be exchangeable regimens in intermediate- and advanced-stage classical HL in pediatric patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.26.9381

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 265

Metadata

Authors
Mauz-Körholz, C., Hasenclever, D., Dörffel, W., Ruschke, K., Pelz, T., Voigt, A., Stiefel, M., Winkler, M., Vilser, C., Dieckmann, K., Karlén, J., Bergsträsser, E., Fosså, A., Mann, G., Hummel, M., Klapper, W., Stein, H., Vordermark, D., Kluge, R., & Körholz, D.
Venue
Journal of Clinical Oncology
Published
2010-08-10
Volume
28
Issue
23
Pages
3680-3686
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2104061870
Cited by
265
References
19
FWCI
7.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study. https://app.cochat.ai/papers/10.1200/jco.2009.26.9381
The paper
Mauz-Körholz, C., Hasenclever, D., Dörffel, W., Ruschke, K., Pelz, T., Voigt, A., Stiefel, M., Winkler, M., Vilser, C., Dieckmann, K., Karlén, J., Bergsträsser, E., Fosså, A., Mann, G., Hummel, M., Klapper, W., Stein, H., Vordermark, D., Kluge, R., & Körholz, D. (2010). Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.26.9381

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.